Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
19.74
-0.30 (-1.50%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,178,359
Open
20.00
Bid (Size)
19.71 (1)
Ask (Size)
20.25 (2)
Prev. Close
20.04
Today's Range
19.52 - 20.29
52wk Range
14.15 - 26.56
Shares Outstanding
162,625,379
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
While growth is established for NASDAQ:ACAD, the stock's valuation remains reasonable.
February 17, 2025
ACADIA PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:ACAD is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Via
Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
+5.79%
+5.79%
1 Month
+10.34%
+10.34%
3 Month
+21.78%
+21.78%
6 Month
+26.78%
+26.78%
1 Year
-20.56%
-20.56%
More News
Read More
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
January 14, 2025
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
December 31, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
December 31, 2024
Via
Benzinga
Exposures
Fossil Fuels
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday
December 31, 2024
Via
Benzinga
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
December 19, 2024
From
Acadia Pharmaceuticals
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
December 11, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
December 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
November 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 21, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
November 14, 2024
Via
MarketBeat
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
November 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
November 05, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
October 10, 2024
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.